Today is Rare Disease Day and we at Lumira Ventures are proud of our ongoing commitment to supporting the discovery, development and commercialization of innovative therapeutic products with the potential to materially impact the lives of patients suffering from rare diseases. In partnership with Angelini Pharma, our Angelini Lumira Biosciences Fund (ALBF) is investing in, and helping to build companies developing first/best-in class medicines addressing rare diseases. We launched the ALBF in July 2021, and have already closed on investments in two exciting and potentially transformative companies: GenEP, which is developing therapies to address unmet needs in rare genetic epilepsies; and Congruence Therapeutics, which is developing stabilizers for misfolded proteins driving various rare indications. With so many patients suffering from rare diseases with high-unmet medical need, we at Lumira Ventures remain laser-focused on identifying and supporting the very best mission driven companies that are focused on bringing a meaningful improvements in these patients’ lives.